10 Top Gene Therapy Companies in 2021
Three years ago, the FDA granted landmark approval to the first in vivo gene therapy for treating an inherited eye disease. Luxturna, an AAV2 based gene therapy developed by Spark Therapeutics, bagged regulatory win to treat this eye disease called Leber congenital amaurosis. Since then, the agency has approved Zolgensma, a spinal muscular atrophy treatment, and has given green light to dozens of small and big biotechs to start clinical trials for their gene therapies.
GO Prime with only $1.49 now
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13